CRVS — Corvus Pharmaceuticals, Inc.

Summary of Corvus Pharmaceuticals Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Research and Development Expenses: Increased to $8.5 million from $5.2 million in Q3 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib.
• Net Loss: Reported at $10.2 million, significantly improved from a net loss of $40.2 million in Q3 2024, which included a substantial noncash loss related to warrant liability.
• Cash Position: As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $65.7 million, up from $52 million at the end of 2024, with sufficient funds expected to support operations into Q4 2026.

2. Strategic Updates and Business Highlights

• Soquelitinib Development: Focus remains on soquelitinib for atopic dermatitis and T cell lymphomas. Key milestones include:
  • Completed enrollment in the extension Cohort 4 of the Phase I trial, with results expected in January 2026.
  • Anticipation of initiating a Phase II trial for atopic dermatitis in early Q1 2026, targeting patients who have failed prior systemic therapies.
  • Continued enrollment in a Phase III trial for relapsed peripheral T cell lymphoma (PTCL), aiming for interim data in late 2026.
• Clinical Data: Cohort 3 of the Phase I trial showed promising efficacy, with a 64.8% mean reduction in EASI score at day 28, indicating potential for deeper responses with longer treatment durations.
• Leadership Expansion: Appointment of David Moore to the Board of Directors, enhancing strategic capabilities.

3. Forward Guidance and Outlook

• Upcoming Data Releases: Results from Cohort 4 in January 2026 and presentations at the American Society of Hematology (ASH) meeting in December 2025 are anticipated to provide further insights into soquelitinib's efficacy.
• Long-Term Plans: The company is optimistic about expanding soquelitinib into additional indications beyond atopic dermatitis, including asthma and other immune-related diseases.

4. Bad News, Challenges, or Points of Concern

• Increased R&D Costs: The rise in R&D expenses may indicate higher burn rates as the company progresses through clinical trials.
• Market Competition: The potential for competition in both the atopic dermatitis and oncology spaces could pose challenges, especially as other companies advance similar therapies.
• Funding Needs: Future expansion into additional indications will likely require raising capital, which could dilute existing shareholder value or depend on favorable market conditions.

5. Notable Q&A Insights

• ASH Presentation Context: Management expressed enthusiasm about the upcoming ASH presentation, highlighting impressive overall survival data in T cell lymphoma, which could bolster confidence in soquelitinib's efficacy.
• Efficacy Expectations: There is cautious optimism regarding the efficacy of soquelitinib in the Phase II trial, with management emphasizing the importance of consistency in results and the potential for improved outcomes with extended treatment duration.
• Subgroup Analysis Plans: While there are plans for post hoc analyses to evaluate efficacy in patients previously treated with JAK inhibitors and Dupixent, the study will not be powered specifically for these subgroups due to insufficient data.

Overall, Corvus Pharmaceuticals is navigating a pivotal phase in its development of soquelitinib, with promising clinical data and strategic plans in place, while also facing challenges related to funding and market competition.